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DISCUSSION
Dr Ronald M. Fairman (Philadelphia, Pa). This is a very
interesting paper, and I commend your whole group for looking at
this very carefully. I have a number of questions. My understanding
of the manuscript is that you’ve presented 11 delayed conversions:
7 were ruptures and 4 were due to progressive enlargement. Two
of the 11 patients died perioperatively. I would be interested to
know what endograft types were in those two patients who died
and whether that mattered. You commented in the paper that the
mortality in the group where you completely excised the graft was
67%, so I’m interested to know whether perhaps were they supra-
renal grafts versus infrarenal grafts?
I really like your approach that you have taken, which is a
selective approach to managing these complications. I have been
impressed with the explants that I have done that, in fact, there is
very little incorporation, though, regardless of whatever the graft
type is, whether it is an exoskeleton or an endoskeleton, they seem
to slide right out of the sac when I open the sac. Have you seen
much incorporation with any of these cases that you’ve done?
How did the ruptures present? Are we protected? Do we have
more time to intervene on ruptures than with a standard aortic
rupture? Are there any differences?
If I sort out the numbers correctly, it looks as if 4 of the 49
Talent grafts that you implanted required conversion. That’s about
an 8% or 9% incidence, and it seems to me to not bode very well for
the Talent device. That certainly is very different from our experi-
ence. It’s different from every other Talent report that I’ve heard.
And I’m just curious whether you can shed any more light on that?
Dr Evan C. Lipsitz. Thank you Dr Fairman. Of the two
patients who died, one had a surgeon-made graft (MEGS), and the
other had a Talent graft. In both patients, although the grafts were
suprarental, it was more the severity of the presentation than the
type of graft that contributed to the mortality. One of the patients
had a known endoleak and refused intervention. His aneurysm
increased in size from 7 to 12 cm, and he presented to the hospital
hypotensive and with extensive blood loss. He did, in fact, have
good incorporation of the proximal Palmaz stent of the MEGS
graft and required a supraceliac clamp for what was a difficult graft
extrication.
The other patient had an aortoenteric fistula and had more
septic-related complications than anything else. Although in terms
of those two patients, it is probably a case of sicker patients just
doing worse, one could say that the presence of suprarenal stents
that have not migrated added complexity.
Regarding your second question about the graft sliding out, in
many cases we also did not find significant incorporation. In several
cases we were able to clamp infrarenally because the grafts had
slipped down. In several other cases, even when we required a
supraceliac balloon, the graft was relatively easy to remove.
Whether this will be different as the industry increases and im-
proves proximal fixation devices such as suprarenal stents, hooks,
and barbs, these kinds of cases are going to become more difficult,
although I hope that we will have to do them less often. One issue
is that in the absence of graft migration, it is difficult to assess
preoperatively how difficult it will be to remove the graft. The
presence of an exoskeleton will likely not increase incorporation
but may increase trauma to the vessel when removed.
As to whether or not we are protected, I think some early
literature suggested that we might be. In our series several patients
presented with “contained” rupture, which enabled them to return
to our hospital for repair. That, in and of itself, may represent a
somewhat selected group of patients. Overall, I do not think the
presence of an endograft is protective nor that the time frame for
repair should be any different than for de novo rupture, but again,
the approach must be individualized.
Finally, regarding the relatively high delayed conversion rate
for the Talent grafts (which was also seen in the Vanguard grafts),
I did not do a graft-specific analysis because the length of follow-up
for each of the grafts is really quite different.
Dr Dhiraj M. Shah (Albany, NY). Dr Lipsitz, I enjoyed your
presentation. Were the seven patients who had ruptures lost to
follow-up, or did you have any premonition that something was
happening with any of these patients, like endoleak or slow migra-
tion? Could the ruptures have beeen prevented?
Dr Lipsitz. Thank you, Dr Shah. In the majority of these
patients we did not have any indication of impending rupture on
follow-up. One patient had a known type I endoleak and refused
further intervention. Another patient with migration of the prox-
imal graft had a CAT scan and angiogram and was being scheduled
for explant, but had a rupture prior to his elective repair. A third
patient had aneurysm enlargement with a type 2 endoleak and was
being medically optimized in the hospital prior to repair when his
rupture occurred. As an example of the remaining cases, I showed
a 12-month CT without enlargement in a patient who suddenly, at
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18 months, presented with type I endoleak and rupture. If we had
seen type I endoleak, migration, or significant increase in aneurysm
diameter, those patients would have been expeditiously repaired.
Dr Daniel G. Clair (New York, NY). Just two quick ques-
tions. One, maybe I missed this, did you say all of these patient
have had rupture prior to their conversion? And the second is,
technically, when you do these, are you placing the clamp on
before you open the aneurysm? We did probably 8 or 10 of these in
Cleveland before I left, and normally the technique that we used
had been just to open up the aneurysm to inspect the graft and see
where the endoleak was, with a clamp in place in either a suprace-
liac or suprarenal position, depending upon the graft’s position
and the graft that we were trying to treat. Did you do that or did
you clamp always before you opened up the aneurysm sac?
Dr Lipsitz. Seven of the patients presented with rupture.
There were two cases in which we opened the aneurysm sac with
the clamp in position but not closed. One was a case of endoten-
sion and the other was a case of type II endoleak.
Dr Jeffrey P. Carpenter (Philadelphia, Pa). Congratulations
on a very provocative, interesting paper that reinforces my own bias
that endovascular aneurysm repair is not something to be entered
into lightly and perhaps should be reserved only for high-risk
patients, since it is not simply the case that you can always just turn
it into an open repair later if things do not work out.
Your high morbidity and mortality has that made you more
interested in trying to find an endovascular solution rather than
conversion? I noted some lumbar endoleaks that perhaps could
have been treated with a translumbar approach, the type I leak with
the aneurysm that fell into the sac, the stent graft that perhaps you
could have used a suprarenal cuff to fix. What are your thoughts?
Dr. Lipsitz. Thank you, Dr Carpenter. I think that is abso-
lutely right. Many of these patients presented and were operated
on before we were doing a translumbar approach. And now that we
have improved availability as well as design of proximal cuffs, I
suspect that these will be used more frequently. I would reempha-
size that a number of patients in this series as well as in the total
group undergoing EVAR had secondary endovascular interven-
tions.
Dr Peter L. Faries (New York, NY). Can you discuss for us
how you decide whether or not to remove the graft completely and
which portion of the endograft you might leave in place? Are there
guidelines that you have developed on the basis of your experience?
Dr Lipsitz. That is a decision that is made at the time of
operation. The bottom line is this: is it easy or not? If there is
migration, either proximally or distally, and if the graft is not
secure, we will take it out. If the graft is well incorporated and
removal may be difficult or dangerous, especially the distal portion,
we will leave it in. If we have a well-incorporated proximal portion
and the distal limb has popped out, rather than traumatize the
visceral and renal segment, we will cut the graft, including the
stents, and sew the graft, incorporating, just as we do distally, aorta
and residual endograft.
Dr Faries. And are any of these graft types harder or easier to
remove intraoperatively of the types that were involved in your
conversions?
Dr Lipsitz. I think that the more suprarenal the stent and the
stiffer the stent, the more difficult.
Dr Manish Mehta (Albany, NY). Since most of these patients
presented with rupture—and I’m presuming that the rupture
occurred at least a year or so after the repair, although I don’t know
that for a fact—I wonder if that modifies your follow-ups, since
most people do follow-up patients at 1 month, 6 months, and then
yearly thereafter after the first year. I wonder if that should be
changed a little bit, with each patient getting every-6-months
follow-ups to detect problems that maybe could prevent rupture.
Dr Lipsitz. Well, that’s a good point. Perhaps for the first 2 or
3 years following EVAR, we should go to an every-6-months
follow-up. But one of the other issues that comes up is the notion
of complications of today occurring in grafts of yesterday. One
could always say that the grafts are better now so we do not need to
do that. I am not sure if that is a reason not to alter follow-up, but
I am sure that this will continue to be a dynamic issue.
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